#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=This series of 25 articles ( 22 original articles , 3 reviews ) is presented by international leaders in bioinformatics and biostatistics .
1-1	0-4	This	abstract[1]	new[1]	_	_
1-2	5-11	series	abstract[1]	new[1]	_	_
1-3	12-14	of	abstract[1]	new[1]	_	_
1-4	15-17	25	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-5	18-26	articles	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-6	27-28	(	_	_	_	_
1-7	29-31	22	abstract[3]	new[3]	coref	2-5[0_3]
1-8	32-40	original	abstract[3]	new[3]	_	_
1-9	41-49	articles	abstract[3]	new[3]	_	_
1-10	50-51	,	_	_	_	_
1-11	52-53	3	abstract[4]	new[4]	_	_
1-12	54-61	reviews	abstract[4]	new[4]	_	_
1-13	62-63	)	_	_	_	_
1-14	64-66	is	_	_	_	_
1-15	67-76	presented	_	_	_	_
1-16	77-79	by	_	_	_	_
1-17	80-93	international	person[5]	new[5]	_	_
1-18	94-101	leaders	person[5]	new[5]	_	_
1-19	102-104	in	person[5]	new[5]	_	_
1-20	105-119	bioinformatics	person[5]|abstract	new[5]|new	coref	2-22
1-21	120-123	and	person[5]	new[5]	_	_
1-22	124-137	biostatistics	person[5]|abstract	new[5]|new	_	_
1-23	138-139	.	_	_	_	_

#Text=This original series of articles details emerging approaches that leverage artificial intelligence and machine learning algorithms to improve the utility of bioinformatics applications in cancer biology .
2-1	140-144	This	abstract[8]	new[8]	coref	11-4[93_8]
2-2	145-153	original	abstract[8]	new[8]	_	_
2-3	154-160	series	abstract[8]	new[8]	_	_
2-4	161-163	of	abstract[8]	new[8]	_	_
2-5	164-172	articles	abstract[8]|abstract	new[8]|giv	_	_
2-6	173-180	details	_	_	_	_
2-7	181-189	emerging	abstract[10]	new[10]	coref	3-10[20_10]
2-8	190-200	approaches	abstract[10]	new[10]	_	_
2-9	201-205	that	_	_	_	_
2-10	206-214	leverage	_	_	_	_
2-11	215-225	artificial	abstract[11]	new[11]	_	_
2-12	226-238	intelligence	abstract[11]	new[11]	_	_
2-13	239-242	and	_	_	_	_
2-14	243-250	machine	abstract[12]	new[12]	_	_
2-15	251-259	learning	abstract[12]	new[12]	_	_
2-16	260-270	algorithms	abstract[12]	new[12]	_	_
2-17	271-273	to	_	_	_	_
2-18	274-281	improve	_	_	_	_
2-19	282-285	the	abstract[13]	new[13]	_	_
2-20	286-293	utility	abstract[13]	new[13]	_	_
2-21	294-296	of	abstract[13]	new[13]	_	_
2-22	297-311	bioinformatics	abstract[13]|abstract|abstract[15]	new[13]|giv|new[15]	_	_
2-23	312-324	applications	abstract[13]|abstract[15]	new[13]|new[15]	_	_
2-24	325-327	in	abstract[13]|abstract[15]	new[13]|new[15]	_	_
2-25	328-334	cancer	abstract[13]|abstract[15]|abstract|abstract[17]	new[13]|new[15]|new|new[17]	coref	12-32
2-26	335-342	biology	abstract[13]|abstract[15]|abstract[17]	new[13]|new[15]|new[17]	_	_
2-27	343-344	.	_	_	_	_

#Text=Importantly , the issue also addresses the limitations of current approaches to analyzing high throughput datasets by providing support for novel methods that can be used to improve complex multi-variable analysis .
3-1	345-356	Importantly	_	_	_	_
3-2	357-358	,	_	_	_	_
3-3	359-362	the	abstract[18]	new[18]	_	_
3-4	363-368	issue	abstract[18]	new[18]	_	_
3-5	369-373	also	_	_	_	_
3-6	374-383	addresses	_	_	_	_
3-7	384-387	the	abstract[19]	new[19]	_	_
3-8	388-399	limitations	abstract[19]	new[19]	_	_
3-9	400-402	of	abstract[19]	new[19]	_	_
3-10	403-410	current	abstract[19]|abstract[20]	new[19]|giv[20]	coref	9-9[76_20]
3-11	411-421	approaches	abstract[19]|abstract[20]	new[19]|giv[20]	_	_
3-12	422-424	to	_	_	_	_
3-13	425-434	analyzing	_	_	_	_
3-14	435-439	high	abstract[22]	new[22]	coref	5-15[33_22]
3-15	440-450	throughput	abstract|abstract[22]	new|new[22]	_	_
3-16	451-459	datasets	abstract[22]	new[22]	_	_
3-17	460-462	by	_	_	_	_
3-18	463-472	providing	_	_	_	_
3-19	473-480	support	abstract[23]	new[23]	coref	14-60[0_23]
3-20	481-484	for	abstract[23]	new[23]	_	_
3-21	485-490	novel	abstract[23]|abstract[24]	new[23]|new[24]	_	_
3-22	491-498	methods	abstract[23]|abstract[24]	new[23]|new[24]	_	_
3-23	499-503	that	_	_	_	_
3-24	504-507	can	_	_	_	_
3-25	508-510	be	_	_	_	_
3-26	511-515	used	_	_	_	_
3-27	516-518	to	_	_	_	_
3-28	519-526	improve	_	_	_	_
3-29	527-534	complex	abstract[25]	new[25]	coref	6-17[41_25]
3-30	535-549	multi-variable	abstract[25]	new[25]	_	_
3-31	550-558	analysis	abstract[25]	new[25]	_	_
3-32	559-560	.	_	_	_	_

#Text=For example , in order to help identify clinically meaningful genes , Shen et al.
4-1	561-564	For	_	_	_	_
4-2	565-572	example	_	_	_	_
4-3	573-574	,	_	_	_	_
4-4	575-577	in	_	_	_	_
4-5	578-583	order	_	_	_	_
4-6	584-586	to	_	_	_	_
4-7	587-591	help	_	_	_	_
4-8	592-600	identify	_	_	_	_
4-9	601-611	clinically	abstract[26]	new[26]	coref	7-16[0_26]
4-10	612-622	meaningful	abstract[26]	new[26]	_	_
4-11	623-628	genes	abstract[26]	new[26]	_	_
4-12	629-630	,	_	_	_	_
4-13	631-635	Shen	person	new	_	_
4-14	636-638	et	_	_	_	_
4-15	639-642	al.	_	_	_	_

#Text=demonstrate how the implementation of a knockoff procedure can control false discovery rates in next-generation datasets with relatively small sample sizes .
5-1	643-654	demonstrate	_	_	_	_
5-2	655-658	how	_	_	_	_
5-3	659-662	the	abstract[28]	new[28]	_	_
5-4	663-677	implementation	abstract[28]	new[28]	_	_
5-5	678-680	of	abstract[28]	new[28]	_	_
5-6	681-682	a	abstract[28]|abstract[30]	new[28]|new[30]	_	_
5-7	683-691	knockoff	abstract[28]|event|abstract[30]	new[28]|new|new[30]	_	_
5-8	692-701	procedure	abstract[28]|abstract[30]	new[28]|new[30]	_	_
5-9	702-705	can	_	_	_	_
5-10	706-713	control	_	_	_	_
5-11	714-719	false	abstract[32]	new[32]	_	_
5-12	720-729	discovery	abstract|abstract[32]	new|new[32]	_	_
5-13	730-735	rates	abstract[32]	new[32]	_	_
5-14	736-738	in	abstract[32]	new[32]	_	_
5-15	739-754	next-generation	abstract[32]|abstract[33]	new[32]|giv[33]	coref	9-18[80_33]
5-16	755-763	datasets	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
5-17	764-768	with	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
5-18	769-779	relatively	abstract[32]|abstract[33]|quantity[35]	new[32]|giv[33]|new[35]	_	_
5-19	780-785	small	abstract[32]|abstract[33]|quantity[35]	new[32]|giv[33]|new[35]	_	_
5-20	786-792	sample	abstract[32]|abstract[33]|object|quantity[35]	new[32]|giv[33]|new|new[35]	_	_
5-21	793-798	sizes	abstract[32]|abstract[33]|quantity[35]	new[32]|giv[33]|new[35]	_	_
5-22	799-800	.	_	_	_	_

#Text=Additionally , tools were developed and validated to address complex problems ranging from tumor heterogeneity to mutation signature analysis .
6-1	801-813	Additionally	_	_	_	_
6-2	814-815	,	_	_	_	_
6-3	816-821	tools	object	new	coref	9-6[75_0]
6-4	822-826	were	_	_	_	_
6-5	827-836	developed	_	_	_	_
6-6	837-840	and	_	_	_	_
6-7	841-850	validated	_	_	_	_
6-8	851-853	to	_	_	_	_
6-9	854-861	address	_	_	_	_
6-10	862-869	complex	abstract[37]	new[37]	_	_
6-11	870-878	problems	abstract[37]	new[37]	_	_
6-12	879-886	ranging	_	_	_	_
6-13	887-891	from	_	_	_	_
6-14	892-897	tumor	abstract|abstract[39]	new|new[39]	coref|coref	7-5[0_39]|8-9
6-15	898-911	heterogeneity	abstract[39]	new[39]	_	_
6-16	912-914	to	abstract[39]	new[39]	_	_
6-17	915-923	mutation	abstract[39]|abstract|abstract[41]	new[39]|new|giv[41]	coref|coref	8-20[64_41]|8-52
6-18	924-933	signature	abstract[39]|abstract[41]	new[39]|giv[41]	_	_
6-19	934-942	analysis	abstract[39]|abstract[41]	new[39]|giv[41]	_	_
6-20	943-944	.	_	_	_	_

#Text=For example , intertumor heterogeneity scores were characterized from >2800 tumors and used to identify genes associated with high heterogeneity including histone methyltransferase SETD2 and DNA methyltransferase DNMT3A , which were then validated by CRISPR/CAS9 in experimental systems .
7-1	945-948	For	_	_	_	_
7-2	949-956	example	_	_	_	_
7-3	957-958	,	_	_	_	_
7-4	959-969	intertumor	abstract[43]	new[43]	_	_
7-5	970-983	heterogeneity	abstract|abstract[43]	giv|new[43]	coref	7-19[46_0]
7-6	984-990	scores	abstract[43]	new[43]	_	_
7-7	991-995	were	_	_	_	_
7-8	996-1009	characterized	_	_	_	_
7-9	1010-1014	from	_	_	_	_
7-10	1015-1020	>2800	object[44]	new[44]	_	_
7-11	1021-1027	tumors	object[44]	new[44]	_	_
7-12	1028-1031	and	_	_	_	_
7-13	1032-1036	used	_	_	_	_
7-14	1037-1039	to	_	_	_	_
7-15	1040-1048	identify	_	_	_	_
7-16	1049-1054	genes	abstract	giv	coref	8-14[60_0]
7-17	1055-1065	associated	_	_	_	_
7-18	1066-1070	with	_	_	_	_
7-19	1071-1075	high	abstract[46]	giv[46]	_	_
7-20	1076-1089	heterogeneity	abstract[46]	giv[46]	_	_
7-21	1090-1099	including	abstract[46]	giv[46]	_	_
7-22	1100-1107	histone	abstract[46]|person|abstract[49]	giv[46]|new|new[49]	_	_
7-23	1108-1125	methyltransferase	abstract[46]|object|abstract[49]	giv[46]|new|new[49]	coref	7-27
7-24	1126-1131	SETD2	abstract[46]|abstract[49]	giv[46]|new[49]	_	_
7-25	1132-1135	and	abstract[46]	giv[46]	_	_
7-26	1136-1139	DNA	abstract[46]|abstract|abstract[52]	giv[46]|new|new[52]	_	_
7-27	1140-1157	methyltransferase	abstract[46]|object|abstract[52]	giv[46]|giv|new[52]	_	_
7-28	1158-1164	DNMT3A	abstract[46]|abstract[52]	giv[46]|new[52]	_	_
7-29	1165-1166	,	_	_	_	_
7-30	1167-1172	which	_	_	_	_
7-31	1173-1177	were	_	_	_	_
7-32	1178-1182	then	_	_	_	_
7-33	1183-1192	validated	_	_	_	_
7-34	1193-1195	by	_	_	_	_
7-35	1196-1207	CRISPR/CAS9	abstract[53]	new[53]	_	_
7-36	1208-1210	in	abstract[53]	new[53]	_	_
7-37	1211-1223	experimental	abstract[53]|abstract[54]	new[53]|new[54]	coref	14-59[135_54]
7-38	1224-1231	systems	abstract[53]|abstract[54]	new[53]|new[54]	_	_
7-39	1232-1233	.	_	_	_	_

#Text=Likewise , a tool was derived to infer tumor RNA expression signatures of genes with copy loss to support gene-loss driven biomarker analysis , and , a weight-matrix based approach was used to highlight the distribution of APOBEC and AID-related gene signatures in multiple cancers that drive subsets of the somatic mutation spectra .
8-1	1234-1242	Likewise	_	_	_	_
8-2	1243-1244	,	_	_	_	_
8-3	1245-1246	a	object[55]	new[55]	coref	10-13[0_55]
8-4	1247-1251	tool	object[55]	new[55]	_	_
8-5	1252-1255	was	_	_	_	_
8-6	1256-1263	derived	_	_	_	_
8-7	1264-1266	to	_	_	_	_
8-8	1267-1272	infer	_	_	_	_
8-9	1273-1278	tumor	abstract|object[59]	giv|new[59]	coref	8-40[69_59]
8-10	1279-1282	RNA	organization|object[59]	new|new[59]	_	_
8-11	1283-1293	expression	abstract|object[59]	new|new[59]	coref	19-30
8-12	1294-1304	signatures	object[59]	new[59]	_	_
8-13	1305-1307	of	object[59]	new[59]	_	_
8-14	1308-1313	genes	object[59]|abstract[60]	new[59]|giv[60]	coref	24-23[235_60]
8-15	1314-1318	with	object[59]|abstract[60]	new[59]|giv[60]	_	_
8-16	1319-1323	copy	object[59]|abstract[60]|object|abstract[62]	new[59]|giv[60]|new|new[62]	_	_
8-17	1324-1328	loss	object[59]|abstract[60]|abstract[62]	new[59]|giv[60]|new[62]	_	_
8-18	1329-1331	to	_	_	_	_
8-19	1332-1339	support	_	_	_	_
8-20	1340-1349	gene-loss	abstract[64]	giv[64]	coref	9-16[77_64]
8-21	1350-1356	driven	abstract[64]	giv[64]	_	_
8-22	1357-1366	biomarker	abstract|abstract[64]	new|giv[64]	_	_
8-23	1367-1375	analysis	abstract[64]	giv[64]	_	_
8-24	1376-1377	,	_	_	_	_
8-25	1378-1381	and	_	_	_	_
8-26	1382-1383	,	_	_	_	_
8-27	1384-1385	a	abstract[65]	new[65]	coref	17-2[159_65]
8-28	1386-1399	weight-matrix	abstract[65]	new[65]	_	_
8-29	1400-1405	based	abstract[65]	new[65]	_	_
8-30	1406-1414	approach	abstract[65]	new[65]	_	_
8-31	1415-1418	was	_	_	_	_
8-32	1419-1423	used	_	_	_	_
8-33	1424-1426	to	_	_	_	_
8-34	1427-1436	highlight	_	_	_	_
8-35	1437-1440	the	abstract[66]	new[66]	_	_
8-36	1441-1453	distribution	abstract[66]	new[66]	_	_
8-37	1454-1456	of	abstract[66]	new[66]	_	_
8-38	1457-1463	APOBEC	abstract[66]|abstract	new[66]|new	_	_
8-39	1464-1467	and	_	_	_	_
8-40	1468-1479	AID-related	object[69]	giv[69]	coref	10-19[87_69]
8-41	1480-1484	gene	abstract|object[69]	new|giv[69]	coref	10-19
8-42	1485-1495	signatures	object[69]	giv[69]	_	_
8-43	1496-1498	in	object[69]	giv[69]	_	_
8-44	1499-1507	multiple	object[69]|abstract[70]	giv[69]|new[70]	_	_
8-45	1508-1515	cancers	object[69]|abstract[70]	giv[69]|new[70]	_	_
8-46	1516-1520	that	_	_	_	_
8-47	1521-1526	drive	_	_	_	_
8-48	1527-1534	subsets	abstract[71]	new[71]	_	_
8-49	1535-1537	of	abstract[71]	new[71]	_	_
8-50	1538-1541	the	abstract[71]|abstract[73]	new[71]|new[73]	_	_
8-51	1542-1549	somatic	abstract[71]|abstract[73]	new[71]|new[73]	_	_
8-52	1550-1558	mutation	abstract[71]|abstract|abstract[73]	new[71]|giv|new[73]	_	_
8-53	1559-1566	spectra	abstract[71]|abstract[73]	new[71]|new[73]	_	_
8-54	1567-1568	.	_	_	_	_

#Text=Together these manuscripts demonstrate how novel tools and statistical approaches are being used to refine analysis of large next generation sequencing datasets .
9-1	1569-1577	Together	_	_	_	_
9-2	1578-1583	these	object[74]	new[74]	_	_
9-3	1584-1595	manuscripts	object[74]	new[74]	_	_
9-4	1596-1607	demonstrate	_	_	_	_
9-5	1608-1611	how	_	_	_	_
9-6	1612-1617	novel	object[75]	giv[75]	coref	10-29[0_75]
9-7	1618-1623	tools	object[75]	giv[75]	_	_
9-8	1624-1627	and	object[75]	giv[75]	_	_
9-9	1628-1639	statistical	object[75]|abstract[76]	giv[75]|giv[76]	coref	11-18[96_76]
9-10	1640-1650	approaches	object[75]|abstract[76]	giv[75]|giv[76]	_	_
9-11	1651-1654	are	_	_	_	_
9-12	1655-1660	being	_	_	_	_
9-13	1661-1665	used	_	_	_	_
9-14	1666-1668	to	_	_	_	_
9-15	1669-1675	refine	_	_	_	_
9-16	1676-1684	analysis	abstract[77]	giv[77]	_	_
9-17	1685-1687	of	abstract[77]	giv[77]	_	_
9-18	1688-1693	large	abstract[77]|abstract[80]	giv[77]|giv[80]	coref	11-12[95_80]
9-19	1694-1698	next	abstract[77]|abstract[80]	giv[77]|giv[80]	_	_
9-20	1699-1709	generation	abstract[77]|abstract|abstract[80]	giv[77]|new|giv[80]	_	_
9-21	1710-1720	sequencing	abstract[77]|abstract|abstract[80]	giv[77]|new|giv[80]	_	_
9-22	1721-1729	datasets	abstract[77]|abstract[80]	giv[77]|giv[80]	_	_
9-23	1730-1731	.	_	_	_	_

#Text=Extending these concepts , Veronesi et al. also develop an R-script based tool box for efficient analysis of gene signatures with diagnostic and prognostic variable that highlights how tools are being rapidly adapted into easy-to-use application packages .
10-1	1732-1741	Extending	_	_	_	_
10-2	1742-1747	these	abstract[81]	new[81]	_	_
10-3	1748-1756	concepts	abstract[81]	new[81]	_	_
10-4	1757-1758	,	_	_	_	_
10-5	1759-1767	Veronesi	person	new	_	_
10-6	1768-1770	et	_	_	_	_
10-7	1771-1774	al.	_	_	_	_
10-8	1775-1779	also	_	_	_	_
10-9	1780-1787	develop	_	_	_	_
10-10	1788-1790	an	object[84]	new[84]	_	_
10-11	1791-1799	R-script	object[84]	new[84]	_	_
10-12	1800-1805	based	object[84]	new[84]	_	_
10-13	1806-1810	tool	object|object[84]	giv|new[84]	_	_
10-14	1811-1814	box	object[84]	new[84]	_	_
10-15	1815-1818	for	object[84]	new[84]	_	_
10-16	1819-1828	efficient	object[84]|abstract[85]	new[84]|new[85]	_	_
10-17	1829-1837	analysis	object[84]|abstract[85]	new[84]|new[85]	_	_
10-18	1838-1840	of	object[84]|abstract[85]	new[84]|new[85]	_	_
10-19	1841-1845	gene	object[84]|abstract[85]|abstract|object[87]	new[84]|new[85]|giv|giv[87]	coref|coref	15-10|15-33[150_87]
10-20	1846-1856	signatures	object[84]|abstract[85]|object[87]	new[84]|new[85]|giv[87]	_	_
10-21	1857-1861	with	object[84]|abstract[85]|object[87]	new[84]|new[85]|giv[87]	_	_
10-22	1862-1872	diagnostic	object[84]|abstract[85]|object[87]|abstract[88]	new[84]|new[85]|giv[87]|new[88]	_	_
10-23	1873-1876	and	object[84]|abstract[85]|object[87]|abstract[88]	new[84]|new[85]|giv[87]|new[88]	_	_
10-24	1877-1887	prognostic	object[84]|abstract[85]|object[87]|abstract[88]	new[84]|new[85]|giv[87]|new[88]	_	_
10-25	1888-1896	variable	object[84]|abstract[85]|object[87]|abstract[88]	new[84]|new[85]|giv[87]|new[88]	_	_
10-26	1897-1901	that	_	_	_	_
10-27	1902-1912	highlights	_	_	_	_
10-28	1913-1916	how	_	_	_	_
10-29	1917-1922	tools	object	giv	_	_
10-30	1923-1926	are	_	_	_	_
10-31	1927-1932	being	_	_	_	_
10-32	1933-1940	rapidly	_	_	_	_
10-33	1941-1948	adapted	_	_	_	_
10-34	1949-1953	into	_	_	_	_
10-35	1954-1965	easy-to-use	object[91]	new[91]	_	_
10-36	1966-1977	application	abstract|object[91]	new|new[91]	_	_
10-37	1978-1986	packages	object[91]	new[91]	_	_
10-38	1987-1988	.	_	_	_	_

#Text=Several papers in this series also demonstrate the potential to integrate large and diverse datasets and use machine learning approaches to develop significantly improved multi-variable predictors of clinical outcome .
11-1	1989-1996	Several	object[92]	new[92]	_	_
11-2	1997-2003	papers	object[92]	new[92]	_	_
11-3	2004-2006	in	object[92]	new[92]	_	_
11-4	2007-2011	this	object[92]|abstract[93]	new[92]|giv[93]	_	_
11-5	2012-2018	series	object[92]|abstract[93]	new[92]|giv[93]	_	_
11-6	2019-2023	also	_	_	_	_
11-7	2024-2035	demonstrate	_	_	_	_
11-8	2036-2039	the	abstract[94]	new[94]	coref	21-3[196_94]
11-9	2040-2049	potential	abstract[94]	new[94]	_	_
11-10	2050-2052	to	_	_	_	_
11-11	2053-2062	integrate	_	_	_	_
11-12	2063-2068	large	abstract[95]	giv[95]	coref	13-11[111_95]
11-13	2069-2072	and	abstract[95]	giv[95]	_	_
11-14	2073-2080	diverse	abstract[95]	giv[95]	_	_
11-15	2081-2089	datasets	abstract[95]	giv[95]	_	_
11-16	2090-2093	and	_	_	_	_
11-17	2094-2097	use	_	_	_	_
11-18	2098-2105	machine	abstract[96]	giv[96]	coref	12-6[99_96]
11-19	2106-2114	learning	abstract[96]	giv[96]	_	_
11-20	2115-2125	approaches	abstract[96]	giv[96]	_	_
11-21	2126-2128	to	_	_	_	_
11-22	2129-2136	develop	_	_	_	_
11-23	2137-2150	significantly	abstract[97]	new[97]	_	_
11-24	2151-2159	improved	abstract[97]	new[97]	_	_
11-25	2160-2174	multi-variable	abstract[97]	new[97]	_	_
11-26	2175-2185	predictors	abstract[97]	new[97]	_	_
11-27	2186-2188	of	abstract[97]	new[97]	_	_
11-28	2189-2197	clinical	abstract[97]|abstract[98]	new[97]|new[98]	coref	15-15[0_98]
11-29	2198-2205	outcome	abstract[97]|abstract[98]	new[97]|new[98]	_	_
11-30	2206-2207	.	_	_	_	_

#Text=For example , deep learning artificial intelligence-based approaches were shown to be highly effective at integrating genomic data from multiple sources using de-noising auto-encoders to curate deep features associated with breast cancer clinical characteristics and outcomes .
12-1	2208-2211	For	_	_	_	_
12-2	2212-2219	example	_	_	_	_
12-3	2220-2221	,	_	_	_	_
12-4	2222-2226	deep	_	_	_	_
12-5	2227-2235	learning	_	_	_	_
12-6	2236-2246	artificial	abstract[99]	giv[99]	coref	15-21[145_99]
12-7	2247-2265	intelligence-based	abstract[99]	giv[99]	_	_
12-8	2266-2276	approaches	abstract[99]	giv[99]	_	_
12-9	2277-2281	were	_	_	_	_
12-10	2282-2287	shown	_	_	_	_
12-11	2288-2290	to	_	_	_	_
12-12	2291-2293	be	_	_	_	_
12-13	2294-2300	highly	_	_	_	_
12-14	2301-2310	effective	_	_	_	_
12-15	2311-2313	at	_	_	_	_
12-16	2314-2325	integrating	_	_	_	_
12-17	2326-2333	genomic	abstract[100]	new[100]	coref	14-64[0_100]
12-18	2334-2338	data	abstract[100]	new[100]	_	_
12-19	2339-2343	from	_	_	_	_
12-20	2344-2352	multiple	abstract[101]	new[101]	_	_
12-21	2353-2360	sources	abstract[101]	new[101]	_	_
12-22	2361-2366	using	_	_	_	_
12-23	2367-2377	de-noising	abstract[102]	new[102]	_	_
12-24	2378-2391	auto-encoders	abstract[102]	new[102]	_	_
12-25	2392-2394	to	_	_	_	_
12-26	2395-2401	curate	_	_	_	_
12-27	2402-2406	deep	abstract[103]	new[103]	coref	24-29[236_103]
12-28	2407-2415	features	abstract[103]	new[103]	_	_
12-29	2416-2426	associated	_	_	_	_
12-30	2427-2431	with	_	_	_	_
12-31	2432-2438	breast	place|abstract[106]	new|new[106]	coref	22-16[205_106]
12-32	2439-2445	cancer	abstract|abstract[106]	giv|new[106]	coref	13-14
12-33	2446-2454	clinical	abstract[106]	new[106]	_	_
12-34	2455-2470	characteristics	abstract[106]	new[106]	_	_
12-35	2471-2474	and	_	_	_	_
12-36	2475-2483	outcomes	abstract	new	coref	23-38[225_0]
12-37	2484-2485	.	_	_	_	_

#Text=Moreover , artificial intelligence-driven classification techniques were also used on multiple independent colorectal cancer datasets to identify and verify biomarkers of diagnosis and prognosis that may have important implications for the disease .
13-1	2486-2494	Moreover	_	_	_	_
13-2	2495-2496	,	_	_	_	_
13-3	2497-2507	artificial	abstract[109]	new[109]	_	_
13-4	2508-2527	intelligence-driven	abstract[109]	new[109]	_	_
13-5	2528-2542	classification	abstract|abstract[109]	new|new[109]	coref	19-21
13-6	2543-2553	techniques	abstract[109]	new[109]	_	_
13-7	2554-2558	were	_	_	_	_
13-8	2559-2563	also	_	_	_	_
13-9	2564-2568	used	_	_	_	_
13-10	2569-2571	on	_	_	_	_
13-11	2572-2580	multiple	abstract[111]	giv[111]	coref	16-1[153_111]
13-12	2581-2592	independent	abstract[111]	giv[111]	_	_
13-13	2593-2603	colorectal	abstract[111]	giv[111]	_	_
13-14	2604-2610	cancer	abstract|abstract[111]	giv|giv[111]	coref	14-7
13-15	2611-2619	datasets	abstract[111]	giv[111]	_	_
13-16	2620-2622	to	_	_	_	_
13-17	2623-2631	identify	_	_	_	_
13-18	2632-2635	and	_	_	_	_
13-19	2636-2642	verify	_	_	_	_
13-20	2643-2653	biomarkers	abstract[112]	new[112]	_	_
13-21	2654-2656	of	abstract[112]	new[112]	_	_
13-22	2657-2666	diagnosis	abstract[112]|abstract	new[112]|new	_	_
13-23	2667-2670	and	abstract[112]	new[112]	_	_
13-24	2671-2680	prognosis	abstract[112]|abstract	new[112]|new	coref	18-19
13-25	2681-2685	that	_	_	_	_
13-26	2686-2689	may	_	_	_	_
13-27	2690-2694	have	_	_	_	_
13-28	2695-2704	important	abstract[115]	new[115]	_	_
13-29	2705-2717	implications	abstract[115]	new[115]	_	_
13-30	2718-2721	for	abstract[115]	new[115]	_	_
13-31	2722-2725	the	abstract[115]|abstract[116]	new[115]|new[116]	coref	15-41[152_116]
13-32	2726-2733	disease	abstract[115]|abstract[116]	new[115]|new[116]	_	_
13-33	2734-2735	.	_	_	_	_

#Text=As another example , the Taiwan Cancer Registry database was analyzed to evaluate the value of the Wu co-morbidity score for accuracy in assessing curative-surgery-related 90-day mortality risk and overall survival in patients with locoregionally advanced head and neck cancer ; and , in an alternative approach , Ferroni et al. demonstrate the utility of using machine learning-driven decision support systems to extract data from electronic health records and refine prognostic variables .
14-1	2736-2738	As	_	_	_	_
14-2	2739-2746	another	_	_	_	_
14-3	2747-2754	example	_	_	_	_
14-4	2755-2756	,	_	_	_	_
14-5	2757-2760	the	abstract[120]	new[120]	_	_
14-6	2761-2767	Taiwan	place|abstract[120]	new|new[120]	_	_
14-7	2768-2774	Cancer	abstract|abstract[120]	giv|new[120]	coref	14-39[132_0]
14-8	2775-2783	Registry	abstract|abstract[120]	new|new[120]	_	_
14-9	2784-2792	database	abstract[120]	new[120]	_	_
14-10	2793-2796	was	_	_	_	_
14-11	2797-2805	analyzed	_	_	_	_
14-12	2806-2808	to	_	_	_	_
14-13	2809-2817	evaluate	_	_	_	_
14-14	2818-2821	the	abstract[121]	new[121]	_	_
14-15	2822-2827	value	abstract[121]	new[121]	_	_
14-16	2828-2830	of	abstract[121]	new[121]	_	_
14-17	2831-2834	the	abstract[121]|abstract[124]	new[121]|new[124]	_	_
14-18	2835-2837	Wu	abstract[121]|person|abstract[124]	new[121]|new|new[124]	_	_
14-19	2838-2850	co-morbidity	abstract[121]|abstract|abstract[124]	new[121]|new|new[124]	_	_
14-20	2851-2856	score	abstract[121]|abstract[124]	new[121]|new[124]	_	_
14-21	2857-2860	for	abstract[121]	new[121]	_	_
14-22	2861-2869	accuracy	abstract[121]|abstract	new[121]|new	_	_
14-23	2870-2872	in	_	_	_	_
14-24	2873-2882	assessing	_	_	_	_
14-25	2883-2907	curative-surgery-related	abstract[127]	new[127]	_	_
14-26	2908-2914	90-day	abstract[127]	new[127]	_	_
14-27	2915-2924	mortality	event|abstract[127]	new|new[127]	_	_
14-28	2925-2929	risk	abstract[127]	new[127]	_	_
14-29	2930-2933	and	_	_	_	_
14-30	2934-2941	overall	event[128]	new[128]	coref	18-21[175_128]
14-31	2942-2950	survival	event[128]	new[128]	_	_
14-32	2951-2953	in	event[128]	new[128]	_	_
14-33	2954-2962	patients	event[128]|person[129]	new[128]|new[129]	_	_
14-34	2963-2967	with	event[128]|person[129]	new[128]|new[129]	_	_
14-35	2968-2982	locoregionally	event[128]|person[129]|object[130]	new[128]|new[129]|new[130]	_	_
14-36	2983-2991	advanced	event[128]|person[129]|object[130]	new[128]|new[129]|new[130]	_	_
14-37	2992-2996	head	event[128]|person[129]|object[130]	new[128]|new[129]|new[130]	_	_
14-38	2997-3000	and	event[128]|person[129]	new[128]|new[129]	_	_
14-39	3001-3005	neck	event[128]|person[129]|object|abstract[132]	new[128]|new[129]|new|giv[132]	coref	15-29[0_132]
14-40	3006-3012	cancer	event[128]|person[129]|abstract[132]	new[128]|new[129]|giv[132]	_	_
14-41	3013-3014	;	_	_	_	_
14-42	3015-3018	and	_	_	_	_
14-43	3019-3020	,	_	_	_	_
14-44	3021-3023	in	_	_	_	_
14-45	3024-3026	an	_	_	_	_
14-46	3027-3038	alternative	_	_	_	_
14-47	3039-3047	approach	_	_	_	_
14-48	3048-3049	,	_	_	_	_
14-49	3050-3057	Ferroni	_	_	_	_
14-50	3058-3060	et	_	_	_	_
14-51	3061-3064	al.	_	_	_	_
14-52	3065-3076	demonstrate	_	_	_	_
14-53	3077-3080	the	_	_	_	_
14-54	3081-3088	utility	_	_	_	_
14-55	3089-3091	of	_	_	_	_
14-56	3092-3097	using	_	_	_	_
14-57	3098-3105	machine	_	_	_	_
14-58	3106-3121	learning-driven	_	_	_	_
14-59	3122-3130	decision	abstract|abstract[135]	new|giv[135]	_	_
14-60	3131-3138	support	abstract|abstract[135]	giv|giv[135]	_	_
14-61	3139-3146	systems	abstract[135]	giv[135]	_	_
14-62	3147-3149	to	_	_	_	_
14-63	3150-3157	extract	_	_	_	_
14-64	3158-3162	data	abstract	giv	coref	15-26[148_0]
14-65	3163-3167	from	_	_	_	_
14-66	3168-3178	electronic	object[138]	new[138]	_	_
14-67	3179-3185	health	abstract|object[138]	new|new[138]	_	_
14-68	3186-3193	records	object[138]	new[138]	_	_
14-69	3194-3197	and	_	_	_	_
14-70	3198-3204	refine	_	_	_	_
14-71	3205-3215	prognostic	abstract[139]	new[139]	coref	25-19[247_139]
14-72	3216-3225	variables	abstract[139]	new[139]	_	_
14-73	3226-3227	.	_	_	_	_

#Text=As an alternative approach , and to understand how gene sets may correlate with outcome , Locati et al. utilized self-organizing map approaches to curate publicly available HPV+ cancer data and inferred gene signatures associated with three biological subtypes of the disease .
15-1	3228-3230	As	_	_	_	_
15-2	3231-3233	an	_	_	_	_
15-3	3234-3245	alternative	_	_	_	_
15-4	3246-3254	approach	_	_	_	_
15-5	3255-3256	,	_	_	_	_
15-6	3257-3260	and	_	_	_	_
15-7	3261-3263	to	_	_	_	_
15-8	3264-3274	understand	_	_	_	_
15-9	3275-3278	how	_	_	_	_
15-10	3279-3283	gene	abstract|plant[141]	giv|new[141]	coref|coref	15-33|17-11[163_141]
15-11	3284-3288	sets	plant[141]	new[141]	_	_
15-12	3289-3292	may	_	_	_	_
15-13	3293-3302	correlate	_	_	_	_
15-14	3303-3307	with	_	_	_	_
15-15	3308-3315	outcome	abstract	giv	coref	20-17
15-16	3316-3317	,	_	_	_	_
15-17	3318-3324	Locati	person	new	_	_
15-18	3325-3327	et	_	_	_	_
15-19	3328-3331	al.	_	_	_	_
15-20	3332-3340	utilized	_	_	_	_
15-21	3341-3356	self-organizing	abstract[145]	giv[145]	coref	19-1[177_145]
15-22	3357-3360	map	object|abstract[145]	new|giv[145]	_	_
15-23	3361-3371	approaches	abstract[145]	giv[145]	_	_
15-24	3372-3374	to	_	_	_	_
15-25	3375-3381	curate	_	_	_	_
15-26	3382-3390	publicly	abstract[148]	giv[148]	coref	17-14[164_148]
15-27	3391-3400	available	abstract[148]	giv[148]	_	_
15-28	3401-3405	HPV+	abstract|abstract[148]	new|giv[148]	_	_
15-29	3406-3412	cancer	abstract|abstract[148]	giv|giv[148]	coref	16-8[155_0]
15-30	3413-3417	data	abstract[148]	giv[148]	_	_
15-31	3418-3421	and	_	_	_	_
15-32	3422-3430	inferred	_	_	_	_
15-33	3431-3435	gene	abstract|object[150]	giv|giv[150]	coref	17-11
15-34	3436-3446	signatures	object[150]	giv[150]	_	_
15-35	3447-3457	associated	_	_	_	_
15-36	3458-3462	with	_	_	_	_
15-37	3463-3468	three	abstract[151]	new[151]	_	_
15-38	3469-3479	biological	abstract[151]	new[151]	_	_
15-39	3480-3488	subtypes	abstract[151]	new[151]	_	_
15-40	3489-3491	of	abstract[151]	new[151]	_	_
15-41	3492-3495	the	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
15-42	3496-3503	disease	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
15-43	3504-3505	.	_	_	_	_

#Text=Novel datasets comparing the molecular composition of primary colorectal cancer and brain metastases were also generated .
16-1	3506-3511	Novel	abstract[153]	giv[153]	coref	18-8[171_153]
16-2	3512-3520	datasets	abstract[153]	giv[153]	_	_
16-3	3521-3530	comparing	_	_	_	_
16-4	3531-3534	the	abstract[154]	new[154]	_	_
16-5	3535-3544	molecular	abstract[154]	new[154]	_	_
16-6	3545-3556	composition	abstract[154]	new[154]	_	_
16-7	3557-3559	of	abstract[154]	new[154]	_	_
16-8	3560-3567	primary	abstract[154]|abstract[155]	new[154]|giv[155]	coref	17-28[166_155]
16-9	3568-3578	colorectal	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
16-10	3579-3585	cancer	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
16-11	3586-3589	and	abstract[154]	new[154]	_	_
16-12	3590-3595	brain	abstract[154]|object|abstract[157]	new[154]|new|new[157]	_	_
16-13	3596-3606	metastases	abstract[154]|abstract[157]	new[154]|new[157]	_	_
16-14	3607-3611	were	_	_	_	_
16-15	3612-3616	also	_	_	_	_
16-16	3617-3626	generated	_	_	_	_
16-17	3627-3628	.	_	_	_	_

#Text=In an interesting informatics approach , analysis of steroid hormone-related gene sets in publicly available data identified steroidogenic acute regulatory protein as a potential prognostic biomarker in breast cancer .
17-1	3629-3631	In	_	_	_	_
17-2	3632-3634	an	abstract[159]	giv[159]	_	_
17-3	3635-3646	interesting	abstract[159]	giv[159]	_	_
17-4	3647-3658	informatics	abstract|abstract[159]	new|giv[159]	coref	23-6
17-5	3659-3667	approach	abstract[159]	giv[159]	_	_
17-6	3668-3669	,	_	_	_	_
17-7	3670-3678	analysis	abstract[160]	new[160]	_	_
17-8	3679-3681	of	abstract[160]	new[160]	_	_
17-9	3682-3689	steroid	abstract[160]|object	new[160]|new	_	_
17-10	3690-3705	hormone-related	_	_	_	_
17-11	3706-3710	gene	abstract|plant[163]	giv|giv[163]	coref	24-17[232_0]
17-12	3711-3715	sets	plant[163]	giv[163]	_	_
17-13	3716-3718	in	plant[163]	giv[163]	_	_
17-14	3719-3727	publicly	plant[163]|abstract[164]	giv[163]|giv[164]	coref	19-30[186_164]
17-15	3728-3737	available	plant[163]|abstract[164]	giv[163]|giv[164]	_	_
17-16	3738-3742	data	plant[163]|abstract[164]	giv[163]|giv[164]	_	_
17-17	3743-3753	identified	_	_	_	_
17-18	3754-3767	steroidogenic	abstract[165]	new[165]	_	_
17-19	3768-3773	acute	abstract[165]	new[165]	_	_
17-20	3774-3784	regulatory	abstract[165]	new[165]	_	_
17-21	3785-3792	protein	abstract[165]	new[165]	_	_
17-22	3793-3795	as	_	_	_	_
17-23	3796-3797	a	_	_	_	_
17-24	3798-3807	potential	_	_	_	_
17-25	3808-3818	prognostic	_	_	_	_
17-26	3819-3828	biomarker	_	_	_	_
17-27	3829-3831	in	_	_	_	_
17-28	3832-3838	breast	abstract[166]	giv[166]	coref	18-24[176_166]
17-29	3839-3845	cancer	abstract[166]	giv[166]	_	_
17-30	3846-3847	.	_	_	_	_

#Text=Likewise , a meta-analysis of GEO and TCGA miRNA datasets led to the prioritization of candidate biomarkers of prognosis and overall survival in oral cancer .
18-1	3848-3856	Likewise	_	_	_	_
18-2	3857-3858	,	_	_	_	_
18-3	3859-3860	a	abstract[167]	new[167]	_	_
18-4	3861-3874	meta-analysis	abstract[167]	new[167]	_	_
18-5	3875-3877	of	abstract[167]	new[167]	_	_
18-6	3878-3881	GEO	abstract[167]|person	new[167]|new	_	_
18-7	3882-3885	and	abstract[167]	new[167]	_	_
18-8	3886-3890	TCGA	abstract[167]|abstract|abstract[171]	new[167]|new|giv[171]	coref|coref	22-6[202_171]|22-40
18-9	3891-3896	miRNA	abstract[167]|substance|abstract[171]	new[167]|new|giv[171]	coref	20-3
18-10	3897-3905	datasets	abstract[167]|abstract[171]	new[167]|giv[171]	_	_
18-11	3906-3909	led	_	_	_	_
18-12	3910-3912	to	_	_	_	_
18-13	3913-3916	the	abstract[172]	new[172]	_	_
18-14	3917-3931	prioritization	abstract[172]	new[172]	_	_
18-15	3932-3934	of	abstract[172]	new[172]	_	_
18-16	3935-3944	candidate	abstract[172]|abstract[173]	new[172]|new[173]	_	_
18-17	3945-3955	biomarkers	abstract[172]|abstract[173]	new[172]|new[173]	_	_
18-18	3956-3958	of	abstract[172]|abstract[173]	new[172]|new[173]	_	_
18-19	3959-3968	prognosis	abstract[172]|abstract[173]|abstract	new[172]|new[173]|giv	coref	24-39
18-20	3969-3972	and	abstract[172]	new[172]	_	_
18-21	3973-3980	overall	abstract[172]|event[175]	new[172]|giv[175]	coref	20-8[0_175]
18-22	3981-3989	survival	abstract[172]|event[175]	new[172]|giv[175]	_	_
18-23	3990-3992	in	abstract[172]|event[175]	new[172]|giv[175]	_	_
18-24	3993-3997	oral	abstract[172]|event[175]|abstract[176]	new[172]|giv[175]|giv[176]	coref	22-39[0_176]
18-25	3998-4004	cancer	abstract[172]|event[175]|abstract[176]	new[172]|giv[175]|giv[176]	_	_
18-26	4005-4006	.	_	_	_	_

#Text=Machine learning approaches were similarly used to prioritize relevant miRNAs and validate the high performance of highly ranked miRNAs in classification models , suggesting that prioritization of targets from expression data is a highly effective strategy .
19-1	4007-4014	Machine	abstract[177]	giv[177]	coref	21-6[197_177]
19-2	4015-4023	learning	abstract[177]	giv[177]	_	_
19-3	4024-4034	approaches	abstract[177]	giv[177]	_	_
19-4	4035-4039	were	_	_	_	_
19-5	4040-4049	similarly	_	_	_	_
19-6	4050-4054	used	_	_	_	_
19-7	4055-4057	to	_	_	_	_
19-8	4058-4068	prioritize	abstract	new	coref|none	19-25[183_0]|19-8[0_183]
19-9	4069-4077	relevant	abstract[178]	new[178]	coref	19-17[180_178]
19-10	4078-4084	miRNAs	abstract[178]	new[178]	_	_
19-11	4085-4088	and	_	_	_	_
19-12	4089-4097	validate	_	_	_	_
19-13	4098-4101	the	abstract[179]	new[179]	_	_
19-14	4102-4106	high	abstract[179]	new[179]	_	_
19-15	4107-4118	performance	abstract[179]	new[179]	_	_
19-16	4119-4121	of	abstract[179]	new[179]	_	_
19-17	4122-4128	highly	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
19-18	4129-4135	ranked	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
19-19	4136-4142	miRNAs	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
19-20	4143-4145	in	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
19-21	4146-4160	classification	abstract[179]|abstract[180]|abstract|abstract[182]	new[179]|giv[180]|giv|new[182]	coref	25-16[246_182]
19-22	4161-4167	models	abstract[179]|abstract[180]|abstract[182]	new[179]|giv[180]|new[182]	_	_
19-23	4168-4169	,	_	_	_	_
19-24	4170-4180	suggesting	_	_	_	_
19-25	4181-4185	that	abstract[183]	new[183]	_	_
19-26	4186-4200	prioritization	abstract[183]	new[183]	_	_
19-27	4201-4203	of	abstract[183]	new[183]	_	_
19-28	4204-4211	targets	abstract[183]|abstract[184]	new[183]|new[184]	_	_
19-29	4212-4216	from	abstract[183]|abstract[184]	new[183]|new[184]	_	_
19-30	4217-4227	expression	abstract[183]|abstract[184]|abstract|abstract[186]	new[183]|new[184]|giv|giv[186]	coref	20-3[190_186]
19-31	4228-4232	data	abstract[183]|abstract[184]|abstract[186]	new[183]|new[184]|giv[186]	_	_
19-32	4233-4235	is	_	_	_	_
19-33	4236-4237	a	abstract[187]	new[187]	_	_
19-34	4238-4244	highly	abstract[187]	new[187]	_	_
19-35	4245-4254	effective	abstract[187]	new[187]	_	_
19-36	4255-4263	strategy	abstract[187]	new[187]	_	_
19-37	4264-4265	.	_	_	_	_

#Text=Analysis of miRNA data using an observed survival interval was reported to overcome issues with clinical outcome associations .
20-1	4266-4274	Analysis	abstract[188]	new[188]	_	_
20-2	4275-4277	of	abstract[188]	new[188]	_	_
20-3	4278-4283	miRNA	abstract[188]|substance|abstract[190]	new[188]|giv|giv[190]	coref	22-38[214_190]
20-4	4284-4288	data	abstract[188]|abstract[190]	new[188]|giv[190]	_	_
20-5	4289-4294	using	_	_	_	_
20-6	4295-4297	an	time[192]	new[192]	coref	21-9[198_192]
20-7	4298-4306	observed	time[192]	new[192]	_	_
20-8	4307-4315	survival	event|time[192]	giv|new[192]	_	_
20-9	4316-4324	interval	time[192]	new[192]	_	_
20-10	4325-4328	was	_	_	_	_
20-11	4329-4337	reported	_	_	_	_
20-12	4338-4340	to	_	_	_	_
20-13	4341-4349	overcome	_	_	_	_
20-14	4350-4356	issues	abstract	new	_	_
20-15	4357-4361	with	_	_	_	_
20-16	4362-4370	clinical	abstract[195]	new[195]	_	_
20-17	4371-4378	outcome	abstract|abstract[195]	giv|new[195]	coref	22-24
20-18	4379-4391	associations	abstract[195]	new[195]	_	_
20-19	4392-4393	.	_	_	_	_

#Text=Collectively suggesting the potential of these approaches in this new era of machine learning approaches .
21-1	4394-4406	Collectively	_	_	_	_
21-2	4407-4417	suggesting	_	_	_	_
21-3	4418-4421	the	abstract[196]	giv[196]	_	_
21-4	4422-4431	potential	abstract[196]	giv[196]	_	_
21-5	4432-4434	of	abstract[196]	giv[196]	_	_
21-6	4435-4440	these	abstract[196]|abstract[197]	giv[196]|giv[197]	coref	21-13[200_197]
21-7	4441-4451	approaches	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
21-8	4452-4454	in	_	_	_	_
21-9	4455-4459	this	time[198]	giv[198]	_	_
21-10	4460-4463	new	time[198]	giv[198]	_	_
21-11	4464-4467	era	time[198]	giv[198]	_	_
21-12	4468-4470	of	time[198]	giv[198]	_	_
21-13	4471-4478	machine	time[198]|abstract[200]	giv[198]|giv[200]	coref	23-4[217_200]
21-14	4479-4487	learning	time[198]|abstract|abstract[200]	giv[198]|new|giv[200]	_	_
21-15	4488-4498	approaches	time[198]|abstract[200]	giv[198]|giv[200]	_	_
21-16	4499-4500	.	_	_	_	_

#Text=Finally , additional analysis of similar datasets also highlighted the role of detailed characterization of clinical characteristics in avoiding biological and the clinical outcome analysis bias in large dataset analysis was well demonstrated in the analysis of pancreatic cancer TCGA data by Nicolle et al. .
22-1	4501-4508	Finally	_	_	_	_
22-2	4509-4510	,	_	_	_	_
22-3	4511-4521	additional	abstract[201]	new[201]	coref	22-25[0_201]
22-4	4522-4530	analysis	abstract[201]	new[201]	_	_
22-5	4531-4533	of	abstract[201]	new[201]	_	_
22-6	4534-4541	similar	abstract[201]|abstract[202]	new[201]|giv[202]	coref	23-20[220_202]
22-7	4542-4550	datasets	abstract[201]|abstract[202]	new[201]|giv[202]	_	_
22-8	4551-4555	also	_	_	_	_
22-9	4556-4567	highlighted	_	_	_	_
22-10	4568-4571	the	abstract[203]	new[203]	_	_
22-11	4572-4576	role	abstract[203]	new[203]	_	_
22-12	4577-4579	of	abstract[203]	new[203]	_	_
22-13	4580-4588	detailed	abstract[203]|abstract[204]	new[203]|new[204]	_	_
22-14	4589-4605	characterization	abstract[203]|abstract[204]	new[203]|new[204]	_	_
22-15	4606-4608	of	abstract[203]|abstract[204]	new[203]|new[204]	_	_
22-16	4609-4617	clinical	abstract[203]|abstract[204]|abstract[205]	new[203]|new[204]|giv[205]	_	_
22-17	4618-4633	characteristics	abstract[203]|abstract[204]|abstract[205]	new[203]|new[204]|giv[205]	_	_
22-18	4634-4636	in	_	_	_	_
22-19	4637-4645	avoiding	_	_	_	_
22-20	4646-4656	biological	_	_	_	_
22-21	4657-4660	and	_	_	_	_
22-22	4661-4664	the	abstract[208]	new[208]	_	_
22-23	4665-4673	clinical	abstract[208]	new[208]	_	_
22-24	4674-4681	outcome	abstract|abstract[208]	giv|new[208]	coref	25-12
22-25	4682-4690	analysis	abstract|abstract[208]	giv|new[208]	coref	22-28[210_0]
22-26	4691-4695	bias	abstract[208]	new[208]	_	_
22-27	4696-4698	in	abstract[208]	new[208]	_	_
22-28	4699-4704	large	abstract[208]|abstract[210]	new[208]|giv[210]	_	_
22-29	4705-4712	dataset	abstract[208]|abstract|abstract[210]	new[208]|new|giv[210]	coref	23-28[224_0]
22-30	4713-4721	analysis	abstract[208]|abstract[210]	new[208]|giv[210]	_	_
22-31	4722-4725	was	_	_	_	_
22-32	4726-4730	well	_	_	_	_
22-33	4731-4743	demonstrated	_	_	_	_
22-34	4744-4746	in	_	_	_	_
22-35	4747-4750	the	abstract[211]	new[211]	_	_
22-36	4751-4759	analysis	abstract[211]	new[211]	_	_
22-37	4760-4762	of	abstract[211]	new[211]	_	_
22-38	4763-4773	pancreatic	abstract[211]|abstract[214]	new[211]|giv[214]	coref	24-20[234_214]
22-39	4774-4780	cancer	abstract[211]|abstract|abstract[214]	new[211]|giv|giv[214]	_	_
22-40	4781-4785	TCGA	abstract[211]|abstract|abstract[214]	new[211]|giv|giv[214]	coref	23-29
22-41	4786-4790	data	abstract[211]|abstract[214]	new[211]|giv[214]	_	_
22-42	4791-4793	by	abstract[211]|abstract[214]	new[211]|giv[214]	_	_
22-43	4794-4801	Nicolle	abstract[211]|abstract[214]|person	new[211]|giv[214]|new	_	_
22-44	4802-4804	et	abstract[211]|abstract[214]	new[211]|giv[214]	_	_
22-45	4805-4808	al.	abstract[211]|abstract[214]	new[211]|giv[214]	_	_
22-46	4809-4810	.	_	_	_	_

#Text=More broadly , machine learning-driven informatics approaches , which were demonstrated to have utility in improving statistical analysis of integrated histopathologic datasets , were implemented to analyze the TCGA lung adenocarcinoma dataset as an alternative approach to modeling outcomes .
23-1	4811-4815	More	_	_	_	_
23-2	4816-4823	broadly	_	_	_	_
23-3	4824-4825	,	_	_	_	_
23-4	4826-4833	machine	abstract[217]	giv[217]	_	_
23-5	4834-4849	learning-driven	abstract[217]	giv[217]	_	_
23-6	4850-4861	informatics	abstract|abstract[217]	giv|giv[217]	_	_
23-7	4862-4872	approaches	abstract[217]	giv[217]	_	_
23-8	4873-4874	,	_	_	_	_
23-9	4875-4880	which	_	_	_	_
23-10	4881-4885	were	_	_	_	_
23-11	4886-4898	demonstrated	_	_	_	_
23-12	4899-4901	to	_	_	_	_
23-13	4902-4906	have	_	_	_	_
23-14	4907-4914	utility	abstract	new	coref	24-14[231_0]
23-15	4915-4917	in	_	_	_	_
23-16	4918-4927	improving	_	_	_	_
23-17	4928-4939	statistical	abstract[219]	new[219]	coref	25-4[242_219]
23-18	4940-4948	analysis	abstract[219]	new[219]	_	_
23-19	4949-4951	of	abstract[219]	new[219]	_	_
23-20	4952-4962	integrated	abstract[219]|abstract[220]	new[219]|giv[220]	coref	24-9[230_220]
23-21	4963-4978	histopathologic	abstract[219]|abstract[220]	new[219]|giv[220]	_	_
23-22	4979-4987	datasets	abstract[219]|abstract[220]	new[219]|giv[220]	_	_
23-23	4988-4989	,	_	_	_	_
23-24	4990-4994	were	_	_	_	_
23-25	4995-5006	implemented	_	_	_	_
23-26	5007-5009	to	_	_	_	_
23-27	5010-5017	analyze	_	_	_	_
23-28	5018-5021	the	abstract[224]	giv[224]	_	_
23-29	5022-5026	TCGA	abstract|abstract[224]	giv|giv[224]	_	_
23-30	5027-5031	lung	object|abstract[224]	new|giv[224]	coref	24-6
23-31	5032-5046	adenocarcinoma	abstract|abstract[224]	new|giv[224]	coref	24-4[227_0]
23-32	5047-5054	dataset	abstract[224]	giv[224]	_	_
23-33	5055-5057	as	_	_	_	_
23-34	5058-5060	an	_	_	_	_
23-35	5061-5072	alternative	_	_	_	_
23-36	5073-5081	approach	_	_	_	_
23-37	5082-5084	to	_	_	_	_
23-38	5085-5093	modeling	abstract[225]	giv[225]	_	_
23-39	5094-5102	outcomes	abstract[225]	giv[225]	_	_
23-40	5103-5104	.	_	_	_	_

#Text=Furthermore , using both the lung adenocarcinoma and hepatocellular carcinoma datasets to analyze the utility of integrated gene and imaging data , multiple individual genes , conditional on imaging features , were shown to drive significant improvement in prognosis modeling .
24-1	5105-5116	Furthermore	_	_	_	_
24-2	5117-5118	,	_	_	_	_
24-3	5119-5124	using	_	_	_	_
24-4	5125-5129	both	abstract[227]	giv[227]	_	_
24-5	5130-5133	the	abstract[227]	giv[227]	_	_
24-6	5134-5138	lung	object|abstract[227]	giv|giv[227]	_	_
24-7	5139-5153	adenocarcinoma	abstract[227]	giv[227]	_	_
24-8	5154-5157	and	_	_	_	_
24-9	5158-5172	hepatocellular	abstract|abstract[230]	new|giv[230]	_	_
24-10	5173-5182	carcinoma	abstract|abstract[230]	new|giv[230]	_	_
24-11	5183-5191	datasets	abstract[230]	giv[230]	_	_
24-12	5192-5194	to	_	_	_	_
24-13	5195-5202	analyze	_	_	_	_
24-14	5203-5206	the	abstract[231]	giv[231]	_	_
24-15	5207-5214	utility	abstract[231]	giv[231]	_	_
24-16	5215-5217	of	abstract[231]	giv[231]	_	_
24-17	5218-5228	integrated	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
24-18	5229-5233	gene	abstract[231]|abstract[232]	giv[231]|giv[232]	_	_
24-19	5234-5237	and	abstract[231]	giv[231]	_	_
24-20	5238-5245	imaging	abstract[231]|abstract|abstract[234]	giv[231]|new|giv[234]	_	_
24-21	5246-5250	data	abstract[231]|abstract[234]	giv[231]|giv[234]	_	_
24-22	5251-5252	,	_	_	_	_
24-23	5253-5261	multiple	abstract[235]	giv[235]	_	_
24-24	5262-5272	individual	abstract[235]	giv[235]	_	_
24-25	5273-5278	genes	abstract[235]	giv[235]	_	_
24-26	5279-5280	,	abstract[235]	giv[235]	_	_
24-27	5281-5292	conditional	abstract[235]	giv[235]	_	_
24-28	5293-5295	on	_	_	_	_
24-29	5296-5303	imaging	abstract[236]	giv[236]	_	_
24-30	5304-5312	features	abstract[236]	giv[236]	_	_
24-31	5313-5314	,	_	_	_	_
24-32	5315-5319	were	_	_	_	_
24-33	5320-5325	shown	_	_	_	_
24-34	5326-5328	to	_	_	_	_
24-35	5329-5334	drive	_	_	_	_
24-36	5335-5346	significant	abstract[237]	new[237]	_	_
24-37	5347-5358	improvement	abstract[237]	new[237]	_	_
24-38	5359-5361	in	abstract[237]	new[237]	_	_
24-39	5362-5371	prognosis	abstract[237]|abstract|event[239]	new[237]|giv|new[239]	coref	25-12[245_239]
24-40	5372-5380	modeling	abstract[237]|event[239]	new[237]|new[239]	_	_
24-41	5381-5382	.	_	_	_	_

#Text=These improvements in integrated multi-feature image analysis and molecular analysis for outcome modeling suggest that complex models incorporating diverse variables may be key to making substantial improvements to clinical outcome models in the future .
25-1	5383-5388	These	abstract[240]	new[240]	coref	25-26[248_240]
25-2	5389-5401	improvements	abstract[240]	new[240]	_	_
25-3	5402-5404	in	abstract[240]	new[240]	_	_
25-4	5405-5415	integrated	abstract[240]|abstract[242]	new[240]|giv[242]	coref	25-9[243_242]
25-5	5416-5429	multi-feature	abstract[240]|abstract[242]	new[240]|giv[242]	_	_
25-6	5430-5435	image	abstract[240]|abstract|abstract[242]	new[240]|new|giv[242]	_	_
25-7	5436-5444	analysis	abstract[240]|abstract[242]	new[240]|giv[242]	_	_
25-8	5445-5448	and	abstract[240]	new[240]	_	_
25-9	5449-5458	molecular	abstract[240]|abstract[243]	new[240]|giv[243]	_	_
25-10	5459-5467	analysis	abstract[240]|abstract[243]	new[240]|giv[243]	_	_
25-11	5468-5471	for	abstract[240]|abstract[243]	new[240]|giv[243]	_	_
25-12	5472-5479	outcome	abstract[240]|abstract[243]|abstract|event[245]	new[240]|giv[243]|giv|giv[245]	coref	25-30
25-13	5480-5488	modeling	abstract[240]|abstract[243]|event[245]	new[240]|giv[243]|giv[245]	_	_
25-14	5489-5496	suggest	_	_	_	_
25-15	5497-5501	that	_	_	_	_
25-16	5502-5509	complex	abstract[246]	giv[246]	coref	25-29[250_246]
25-17	5510-5516	models	abstract[246]	giv[246]	_	_
25-18	5517-5530	incorporating	_	_	_	_
25-19	5531-5538	diverse	abstract[247]	giv[247]	_	_
25-20	5539-5548	variables	abstract[247]	giv[247]	_	_
25-21	5549-5552	may	_	_	_	_
25-22	5553-5555	be	_	_	_	_
25-23	5556-5559	key	_	_	_	_
25-24	5560-5562	to	_	_	_	_
25-25	5563-5569	making	_	_	_	_
25-26	5570-5581	substantial	abstract[248]	giv[248]	_	_
25-27	5582-5594	improvements	abstract[248]	giv[248]	_	_
25-28	5595-5597	to	abstract[248]	giv[248]	_	_
25-29	5598-5606	clinical	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
25-30	5607-5614	outcome	abstract[248]|abstract|abstract[250]	giv[248]|giv|giv[250]	_	_
25-31	5615-5621	models	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
25-32	5622-5624	in	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
25-33	5625-5628	the	abstract[248]|abstract[250]|time[251]	giv[248]|giv[250]|new[251]	_	_
25-34	5629-5635	future	abstract[248]|abstract[250]|time[251]	giv[248]|giv[250]|new[251]	_	_
25-35	5636-5637	.	_	_	_	_
